A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of GS-7977 and Ribavirin for 24 Weeks in Subjects With Recurrent Chronic HCV Post Liver Transplant
Phase of Trial: Phase II
Latest Information Update: 17 Nov 2015
At a glance
- Drugs Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 28 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 02 Nov 2013 Findings will be presented at the 64th Annual Meeting of the American Association for the Study of Liver Diseases, according to a Gilead Sciences media release.
- 01 Nov 2013 Planned End Date changed from 1 Oct 2014 to 1 Sep 2014 as reported by ClinicalTrials.gov record.